Accès ouvert
2026
article
OpenAlex
Martin Stuschke, Michael Thomas, Andreas Gröschel, Martin Sebastian et autres
BACKGROUND/OBJECTIVES: Following findings of the PACIFIC trial, consolidation therapy with durvalumab was established as standard of care for patients with unresectable, stage III non-small cell lung cancer (NSCLC) and no disease progression after chemoradiotherapy (CRT). This study evaluated real-world effectiveness of durvalumab …
de
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Fabian Acker, Katharina Wenger, Martin Reck, Cornelius F. Waller et autres
Brain metastases (BM) from non-small cell lung cancer (NSCLC) are a relevant cause of morbidity and mortality. This study aims to identify a population at high risk for BM in order to inform personalized follow-up strategies in the future. We have therefore …
de
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Maximilian Rost, Rieke Fischer, Martin Reck, Thomas Christoph Gauler et autres
Introduction: Recurrent extensive-stage SCLC (ES-SCLC) remains a major therapeutic challenge. Although immune checkpoint inhibitors (2Ls), bispecific antibodies, and antibody-drug conjugates offer promise in early lines, outcomes beyond the second line (2L) remain poor. Real-world data on third line (3L) treatment patterns, clinical …
de
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Peter Jürgen Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald et autres
The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of head-to-head randomized trials comparing these strategies, we …
de
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Peter Jürgen Goebell, Martin Boegemann, Arnd Nusch, Viktor Grünwald et autres
4528 Background: Immune checkpoint inhibitors (CPI), in combination with tyrosine kinase inhibitors (TKI) or with another CPI, expanded the therapeutic options for advanced or metastatic renal cell carcinoma (mRCC) beyond TKI-Monotherapy. However, no head-to-head clinical trials comparing 1st-line (1L) CPI+CPI vs. TKI+CPI …
de
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Thomas W. Decker, Matthias R. Zaiss, Dunja Klein, Antje Hahn et autres
Background: We investigated the efficacy and health-related quality of life (HRQoL) in patients receiving either ribociclib plus endocrine therapy (ET) or chemotherapy with/without bevacizumab as first-line treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer (BC). Patients and Methods: In this randomized, …
de
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Carolin Lennartz, Jonathan Schiefer, Stefan Rotter, Jürgen Hennig et autres
In fMRI, functional connectivity is conventionally characterized by correlations between fMRI time series, which are intrinsically undirected measures of connectivity. Yet, some information about the directionality of network connections can nevertheless be extracted from the matrix of pairwise temporal correlations between all …
de
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Jonathan Schiefer, Alexander Niederbühl, Volker Pernice, Carolin Lennartz et autres
Knowing brain connectivity is of great importance both in basic research and for clinical applications. We are proposing a method to infer directed connectivity from zero-lag covariances of neuronal activity recorded at multiple sites. This allows us to identify causal relations that …
de
(code pays fourni par la source)